MJA
MJA

Tissue plasminogen activator for acute ischaemic stroke

James C Hurley
Med J Aust 2008; 188 (8): . || doi: 10.5694/j.1326-5377.2008.tb01729.x
Published online: 21 April 2008

To the Editor: The recent report on the use of a stroke thrombolysis protocol by Batmanian and colleagues1 raises many issues. The most recent guidelines regarding thrombolytic therapy for ischaemic stroke recommend that “If thrombolytic therapy is to be used . . . consultation with a neurologist or stroke physician is essential before instigating therapy. Strict adherence to the inclusion and exclusion criteria is important . . .”2 Hence, I find the integral role of a neurologist in Batmanian and colleagues’ protocol reassuring.

Online responses are no longer available. Please refer to our instructions for authors page for more information.